MX2016005227A - Polipéptidos de acción prolongada y métodos para su producción y administración. - Google Patents

Polipéptidos de acción prolongada y métodos para su producción y administración.

Info

Publication number
MX2016005227A
MX2016005227A MX2016005227A MX2016005227A MX2016005227A MX 2016005227 A MX2016005227 A MX 2016005227A MX 2016005227 A MX2016005227 A MX 2016005227A MX 2016005227 A MX2016005227 A MX 2016005227A MX 2016005227 A MX2016005227 A MX 2016005227A
Authority
MX
Mexico
Prior art keywords
producing
methods
long
administering same
acting polypeptides
Prior art date
Application number
MX2016005227A
Other languages
English (en)
Inventor
Eyal Fima Udi
Fares Fuad
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/059,134 external-priority patent/US20140113860A1/en
Priority claimed from US14/309,496 external-priority patent/US20150038413A1/en
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of MX2016005227A publication Critical patent/MX2016005227A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)

Abstract

Se describen polipéptidos de la hormona del crecimiento humano modificada por CTP, así como formulaciones farmacéuticas y composiciones farmacéuticas que los comprenden y métodos para producir y usar los mismos.
MX2016005227A 2013-10-21 2014-10-21 Polipéptidos de acción prolongada y métodos para su producción y administración. MX2016005227A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/059,134 US20140113860A1 (en) 2006-02-03 2013-10-21 Long-acting polypeptides and methods of producing and administering same
US14/309,496 US20150038413A1 (en) 2006-02-03 2014-06-19 Long-acting polypeptides and methods of producing and administering same
PCT/IL2014/050910 WO2015059695A1 (en) 2013-10-21 2014-10-21 Long-acting polypeptides and methods of producing and administering same

Publications (1)

Publication Number Publication Date
MX2016005227A true MX2016005227A (es) 2016-08-12

Family

ID=52992360

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005227A MX2016005227A (es) 2013-10-21 2014-10-21 Polipéptidos de acción prolongada y métodos para su producción y administración.
MX2021003908A MX2021003908A (es) 2013-10-21 2016-04-21 Polipeptidos de accion prolongada y metodos para su produccion y administracion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003908A MX2021003908A (es) 2013-10-21 2016-04-21 Polipeptidos de accion prolongada y metodos para su produccion y administracion.

Country Status (20)

Country Link
EP (2) EP3763733A1 (es)
JP (3) JP6640720B2 (es)
KR (3) KR20220130254A (es)
CN (1) CN106163543A (es)
AU (3) AU2014338575B2 (es)
CA (1) CA2928269C (es)
DK (1) DK3060239T3 (es)
ES (1) ES2811068T3 (es)
FR (1) FR22C1035I2 (es)
HR (1) HRP20201114T1 (es)
HU (2) HUE050002T2 (es)
IL (1) IL297219B2 (es)
MX (2) MX2016005227A (es)
NL (1) NL301170I2 (es)
PL (1) PL3060239T3 (es)
PT (1) PT3060239T (es)
RU (1) RU2746943C2 (es)
SI (1) SI3060239T1 (es)
TW (5) TWI720939B (es)
WO (1) WO2015059695A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014338575B2 (en) 2013-10-21 2019-11-07 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
JOP20190019A1 (ar) * 2016-08-30 2019-02-12 Genexine Inc تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
CN109942717A (zh) * 2019-04-24 2019-06-28 上海延立药业有限公司 一种长效重组人促卵泡激素及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE68917883T2 (de) 1988-05-06 1995-02-23 Toray Industries Stabile interferon-beta-zusammensetzung.
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
DK0461200T3 (da) 1989-02-21 1997-03-10 Univ Washington Modificerede former af reproduktionshormoner
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) * 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
DE102007006189B4 (de) * 2007-02-07 2009-07-30 Isotopen Technologien München AG Vorrichtung zum Befüllen eines medizinischen Instruments mit einer radioaktiven Substanz und Verfahren
AU2014338575B2 (en) 2013-10-21 2019-11-07 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same

Also Published As

Publication number Publication date
AU2014338575B2 (en) 2019-11-07
IL297219A (en) 2022-12-01
PL3060239T3 (pl) 2020-11-02
HUE050002T2 (hu) 2020-11-30
IL297219B2 (en) 2024-02-01
CA2928269A1 (en) 2015-04-30
CN106163543A (zh) 2016-11-23
KR20210118490A (ko) 2021-09-30
AU2014338575A1 (en) 2016-06-02
NL301170I2 (nl) 2022-06-16
EP3060239A1 (en) 2016-08-31
JP2020073541A (ja) 2020-05-14
RU2021110927A3 (es) 2021-12-08
EP3060239A4 (en) 2017-05-31
TWI720939B (zh) 2021-03-11
JP2022088521A (ja) 2022-06-14
TW202120120A (zh) 2021-06-01
TW201536327A (zh) 2015-10-01
TWI720940B (zh) 2021-03-11
KR102444140B1 (ko) 2022-09-15
HUS2200014I1 (hu) 2022-05-28
IL297219B1 (en) 2023-10-01
MX2021003908A (es) 2021-06-23
HRP20201114T1 (hr) 2020-10-30
TW201536313A (zh) 2015-10-01
FR22C1035I2 (fr) 2024-02-16
SI3060239T1 (sl) 2020-10-30
PT3060239T (pt) 2020-08-26
NL301170I1 (nl) 2022-04-29
AU2020200874A1 (en) 2020-02-27
JP7445695B2 (ja) 2024-03-07
RU2016119565A (ru) 2018-11-02
FR22C1035I1 (fr) 2022-09-09
TW202317176A (zh) 2023-05-01
JP6640720B2 (ja) 2020-02-05
TWI777407B (zh) 2022-09-11
JP2016535015A (ja) 2016-11-10
KR20160068969A (ko) 2016-06-15
KR20220130254A (ko) 2022-09-26
RU2746943C2 (ru) 2021-04-22
AU2022246472A1 (en) 2022-11-10
RU2021110927A (ru) 2021-05-21
ES2811068T3 (es) 2021-03-10
RU2016119565A3 (es) 2019-01-22
WO2015059695A1 (en) 2015-04-30
CA2928269C (en) 2023-03-14
DK3060239T3 (da) 2020-08-03
EP3060239B1 (en) 2020-05-13
EP3763733A1 (en) 2021-01-13
TW201536312A (zh) 2015-10-01
JP7051797B2 (ja) 2022-04-11

Similar Documents

Publication Publication Date Title
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
MX2018002301A (es) Composiciones de glucano y usos de las mismas.
AU2019268062A1 (en) Benzoquinolone inhibitors of VMAT2
MX2016008448A (es) Conjugados de var2csa-farmaco.
MY188139A (en) Sodium channel modulators for the treatment of pain
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
PH12016501122A1 (en) Delayed release compositions of linaclotide
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
EP3050559A4 (en) Sustained type human growth hormone preparation
MX2015012416A (es) Compuestos heterociclicos y sus usos.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
NZ728401A (en) High purity oritavancin and method of producing same
MX2015011109A (es) Composiciones estables de activador de glucoquinasa.
EP3071214A4 (en) Salacia compositions, methods of treatment by their administration, and methods of their preparation
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
MX2016004078A (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
HK1211594A1 (en) Human relaxin analogue, pharmaceutical composition of same, and pharmaceutical application of same
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).